Wells Fargo lowered the firm’s price target on Nevro to $14 from $17 and keeps an Equal Weight rating on the shares following a change in analysts. The firm is less optimistic about a strong recovery in the core spinal cord stimulation market and sees potential competitive and reimbursement headwinds to Nevro’s growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>